If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  New CLARITIN RediTabs Receives U.S. Marketing Clearance MADISON, N.J., Dec. 23, 1996 -- Schering-Plough Corporation (NYSE: SGP), the leader in the U.S. allergy and respiratory marketplace, announced today that it has received marketing clearance from the U.S. Food and Drug Administration (FDA) for CLARITIN(R) RediTabs(TM) (10 mg loratadine rapidly-disintegrating tablet), the first and only nondrowsy allergy product available in a ready-to-take, rapidly disintegrating tablet. The unique formulation of CLARITIN RediTabs enables the tablet to disintegrate almost instantly in the mouth, conveniently delivering the proven efficacy and safety benefits of regular nonsedating CLARITIN(R) (10 mg loratadine) tablets. CLARITIN RediTabs is indicated for the relief of seasonal allergy symptoms, including itchy, watery eyes; itchy palate; sneezing; and chronic idiopathic urticaria (commonly known as hives). Available by prescription in a once-daily, nonsedating tablet, CLARITIN RediTabs can be administered to adults and children as young as 6 years of age, making it an especially appropriate alternative for children. CLARITIN RediTabs will be available nationwide by prescription in early March 1997, just in time for the spring allergy season. The unique Zydis(R) delivery system of CLARITIN RediTabs is licensed from R.P. Scherer, a leader in drug delivery technology. CLARITIN RediTabs is the newest member of the CLARITIN line, the U.S. allergy market leader and No. 1 antihistamine worldwide. Because taking it does not require water, CLARITIN RediTabs is particularly convenient for allergy sufferers who lead active lifestyles. Available in a pleasant "hint-of-mint" flavor, the product is ready to use wherever needed, even if an individual is traveling, taking a walk, or enjoying any outdoor activity. "Adding CLARITIN RediTabs to our already extensive CLARITIN product line will provide more treatment options for today's allergy sufferers," said Richard W. Zahn, president, Schering Laboratories, the U.S. prescription pharmaceutical marketing arm of Schering-Plough. "The novel delivery system of CLARITIN RediTabs is an innovation in allergy therapy that builds on the proven history and unique benefits of the CLARITIN brand." In controlled clinical trials using the recommended dose, the incidence of the most commonly reported adverse events was comparable to placebo. "CLARITIN RediTabs rapidly dissolving tablet offers convenience and may help improve patient compliance," said Harold Kaiser, M.D., clinical professor of medicine, University of Minnesota Medical School. "This new product is an easy alternative for both adult and child allergy patients who have trouble swallowing pills or don't like taking syrups." Since its U.S. introduction in 1993, the CLARITIN brand -- CLARITIN, CLARITIN(R)-D 12 Hour (5 mg loratadine, 120 mg pseudoephedrine sulfate), CLARITIN(R)-D 24 Hour (10 mg loratadine, 240 mg pseudoephedrine) and CLARITIN(R) Syrup (loratadine 10 mg per ml) -- has provided safe, effective and convenient relief for millions of people who suffer from the symptoms of seasonal allergies. CLARITIN RediTabs continues Schering-Plough's heritage of introducing important innovations to the allergy treatment marketplace. CLARITIN is the only once-daily nonsedating antihistamine without a black-box warning; CLARITIN-D 24 Hour is the only nondrowsy once-a-day combination allergy product; CLARITIN Syrup is the only nondrowsy once-a-day antihistamine for children; and now CLARITIN RediTabs is the only nonsedating rapidly disintegrating tablet for allergies. CLARITIN has more than 3 billion patient days of use worldwide and is the most prescribed antihistamine by U.S. allergists and in the world. For allergy management and treatment information, consumers can call 1-800-CLARITIN or access http://www.claritin.com on the World Wide Web. Schering-Plough manufactures and markets U.S. prescription pharmaceuticals through itsSchering Laboratories , Key Pharmaceuticals and Warrick Pharmaceuticals units. Products include respiratory products, dermatologicals, anti-infectives, anticancer and antiviral products, and cardiovasculars. The company also manufactures and markets animal health products, leading over-the-counter (OTC) pharmaceuticals and personal care products. Schering-Plough Corporation is a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical and health care products worldwide.
|
